Please choose your delivery country and your customer group
Traumatic brain injury (TBI) contributes to 50% of all trauma deaths. The mortality rate for adults following severe TBI (Glasgow Coma Scale < 9) is estimated to be 33%. There is currently no therapy to reverse the primary injury associated with TBI. Over the past 10 years there has been a growing body of literature supporting the use of various progenitor cell types to treat acute neurological injuries such as TBI and stroke. Neural stem cells (adult and embryonic), mesenchymal stromal and multipotent adult progenitor cells, and bone marrow mononucleaer cells (from which MSC and MAPCs are derived) have shown efficacy in preclinical models of TBI/stroke through various mechanisms, however, few groups believe that true neural replacement and integration are the putative mechanisms involved in the observed efficacy. More likely is that the progenitor cell populations are modifying the regional response to injury (inflammatory/reparative vs. regenerative), resulting in improved functional outcomes. Our primary hypothesis is that bone marrow mononuclear cell (BMMNC) autologous transplantation after TBI is safe (harvest and influsion related toxicity) after TBI. Our secondary hypothesis is that functional outcomes measures will improve after BMMNC influsion, (3) BMMNC fusion will reduce BBB permeability and BMMNC is neuroprotective and preserves grey matter and white matter volumes after TBI.